Scarica l'app Stockscreener
2.68
8.06%
0.20
Precedente Chiudi:
$2.48
Aprire:
$2.47
Volume 24 ore:
1.77M
Relative Volume:
0.93
Capitalizzazione di mercato:
$259.73M
Reddito:
$20.76M
Utile/perdita netta:
$-132.49M
Rapporto P/E:
-1.0037
EPS:
-2.67
Flusso di cassa netto:
$-108.55M
1 W Prestazione:
+7.20%
1M Prestazione:
+9.39%
6M Prestazione:
+94.20%
1 anno Prestazione:
-36.04%
Intervallo 1D:
$2.4501
$2.71
Intervallo di 1 settimana:
$2.2901
$2.71
Portata 52W:
$1.085
$5.10
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Nome
C 4 Therapeutics Inc
Settore
Industria
Telefono
(617) 231-0700
Indirizzo
490 ARSENAL WAY, WATERTOWN
Confronta CCCC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.68 | 240.35M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-15 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2024-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Iniziato | Stephens | Equal-Weight |
| 2024-01-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-12-13 | Aggiornamento | Stifel | Hold → Buy |
| 2023-02-24 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Underweight |
| 2022-04-28 | Iniziato | Credit Suisse | Underperform |
| 2022-04-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-10 | Iniziato | JP Morgan | Overweight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-11-23 | Iniziato | BofA Securities | Buy |
| 2021-10-14 | Iniziato | SVB Leerink | Mkt Perform |
| 2021-09-30 | Iniziato | Stifel | Hold |
| 2021-06-04 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-10-27 | Iniziato | BMO Capital Markets | Outperform |
| 2020-10-27 | Iniziato | Jefferies | Buy |
Mostra tutto
C 4 Therapeutics Inc Borsa (CCCC) Ultime notizie
Mineralys Therapeutics reports inducement award under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Mineralys Therapeutics (Nasdaq: MLYS) grants 146K-share inducement option over 4 years - Stock Titan
Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss - Seeking Alpha
CCCC SEC FilingsC4 Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
C4 Therapeutics (NASDAQ: CCCC) fireside chat at Evercore conference Dec. 3 2025 - Stock Titan
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference - MarketScreener
C4 Therapeutics files $400M mixed shelf offering - MSN
C4 Therapeutics Inc files for mixed shelf of up to $400 millionSEC filing - MarketScreener
[S-3] C4 Therapeutics, Inc. Shelf Registration Statement | CCCC SEC FilingForm S-3 - Stock Titan
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
How C4 Therapeutics Inc. stock responds to policy changes2025 Support & Resistance & Growth Focused Investment Plans - newser.com
Using economic indicators to assess C4 Therapeutics Inc. potentialWall Street Watch & Accurate Entry/Exit Alerts - newser.com
C4 Therapeutics Inc. stock trend forecastJuly 2025 Selloffs & Detailed Earnings Play Strategies - newser.com
Stoke Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Yahoo Finance
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Inc. (CCCC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Using data models to predict C4 Therapeutics Inc. stock movement2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - newser.com
What data driven models say about C4 Therapeutics Inc.’s futureMarket Performance Summary & Fast Moving Stock Watchlists - newser.com
Why hedge funds are buying C4 Therapeutics Inc. stockJuly 2025 Patterns & Precise Swing Trade Entry Alerts - newser.com
Volatility clustering patterns for C4 Therapeutics Inc.Trade Entry Summary & Safe Capital Allocation Plans - newser.com
Live market analysis of C4 Therapeutics Inc.July 2025 Recap & Capital Efficient Trade Techniques - newser.com
Is C4 Therapeutics Inc. stock positioned for digital transformationJuly 2025 WrapUp & Low Volatility Stock Suggestions - newser.com
Camp4 Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
How C4 Therapeutics Inc. stock benefits from strong dollarJuly 2025 Retail & Real-Time Volume Analysis Alerts - Fundação Cultural do Pará
Will earnings trigger a reversal in C4 Therapeutics Inc.July 2025 Drop Watch & Weekly Watchlist for Consistent Profits - newser.com
Can trapped investors hope for a rebound in C4 Therapeutics Inc.2025 Earnings Impact & Reliable Price Action Trade Plans - newser.com
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
Fulcrum Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Vera Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
C4 Therapeutics Raises Cash And Wins Wall Street’s Favor - Finimize
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Vera Therapeutics (Nasdaq: VERA) inducement grants: 79,050 options and 39,915 RSUs - Stock Titan
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates - sharewise.com
C4 Therapeutics Reports Q3 2025 Financial Results - TipRanks
C 4 Therapeutics Inc Azioni (CCCC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.76%
2.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):